# KB407 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/kb407

> KB407, sponsored by Krystal Biotech, Inc. (KRYS): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KB407 |
| Codes | KB407 |
| Sponsor | Krystal Biotech, Inc. (KRYS) https://sec-api.dev/companies/krys/catalysts |
| Indications | [cf, regardless of their underlying genotype](https://sec-api.dev/indications/cf-regardless-of-their-underlying-genotype), with cf |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: CF, regardless of their underlying genotype.
- First seen 2025-02-19, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001711279-26-000071): "In July 2023, we announced that we had dosed the first patient in our Phase 1 CORAL-1 study, a multicenter, dose-escalation trial of KB407 in patients with CF that included molecular assessments of CFTR delivery and expression in the third and highest dose cohort." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm
- SEC Form 10-Q (accession 0001711279-26-000057): "In July 2023, we announced that we had dosed the first patient in our Phase 1 CORAL-1 study, a multi-center, dose-escalation trial of KB407 in patients with CF that included molecular assessments of CFTR delivery and expression in the third and highest dose cohort." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm
- SEC Form 10-Q (accession 0001711279-26-000043): "In July 2023, we announced that we had dosed the first patient in our Phase 1 CORAL-1 study, a multi-center, dose-escalation trial of KB407 in patients with CF that included molecular assessments of CFTR delivery and expression in the third and highest dose cohort." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000043/krys-20260331.htm
- SEC Form 10-K (accession 0001711279-26-000016): "In July 2023, we announced that we had dosed the first patient in our Phase 1 CORAL-1 study evaluating KB407, delivered via a nebulizer, for the treatment of patients with CF." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/krys-20251231.htm
- SEC Form 10-Q (accession 0001711279-25-000087): "In July 2023, we announced that we had dosed the first patient in CORAL-1, a Phase 1 multi-center, dose-escalation study evaluating KB407, delivered via a nebulizer, in patients with CF, regardless of their underlying genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm
- SEC Form 10-Q (accession 0001711279-25-000077): "In July 2023, we announced that we had dosed the first patient in CORAL-1, a Phase 1 multi-center, dose-escalation study evaluating KB407, delivered via a nebulizer, in patients with CF, regardless of their underlying genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000077/krys-20250630.htm
- SEC Form 10-Q (accession 0001711279-25-000044): "In July 2023, we announced that we had dosed the first patient in CORAL-1, a Phase 1 multi-center, dose-escalation study evaluating KB407, delivered via a nebulizer, in patients with CF, regardless of their underlying genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000044/krys-20250331.htm
- SEC Form 10-K (accession 0001711279-25-000008): "In July 2023, we announced that we had dosed the first patient in our Phase 1 CORAL-1 study evaluating KB407, delivered via a nebulizer, for the treatment of patients with CF." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000008/krys-20241231.htm
- SEC Form 10-K (accession 0001711279-25-000008): "In July 2023, we announced that we had dosed the first patient in CORAL-1, a Phase 1 multi-center, dose-escalation study evaluating KB407, delivered via a nebulizer, in patients with CF, regardless of their underlying genotype." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000008/krys-20241231.htm

### late 2025: interim data readout

- Status: scheduled. Date confidence: half. Indication: CF, regardless of their underlying genotype.
- First seen 2025-05-06, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001711279-25-000088): "•The Company continues to enroll in Cohort 3 of CORAL-1, the Company's multi-center, dose escalation study evaluating KB407 in patients with CF, regardless of their underlying genotype, and expects to provide an interim data readout for Cohort 3 patients before year end." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000088/a3q25exhibit991pr.htm
- Press release filed with the SEC (EX-99) (accession 0001711279-25-000078): "•The Company has enrolled 4 patients in Cohort 3 of CORAL-1, the Company's multi-center, dose escalation study evaluating KB407 in patients with CF, regardless of their underlying genotype, and expects to provide an interim molecular data readout for Cohort 3 patients before year end." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/a2q25exhibit991pr.htm
- Press release filed with the SEC (EX-99) (accession 0001711279-25-000045): "The Company received full sanctioning of the study protocol by the Cystic Fibrosis Foundation Therapeutic Development Network in January and remains on track for an interim molecular data readout for Cohort 3 patients in mid-2025." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/a1q25exhibit991pr.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/kb407.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KB407 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/kb407

```bibtex
@misc{secapidev_pdufa_kb407_20261116,
  title        = {KB407 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/kb407}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_kb407_20261116","title":"KB407 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/kb407","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
